Anika Return On Capital Employed from 2010 to 2024

ANIK Stock  USD 17.83  0.60  3.48%   
Anika Therapeutics Return On Capital Employed yearly trend continues to be quite stable with very little volatility. Return On Capital Employed may rise above -0.35 this year. From the period between 2010 and 2024, Anika Therapeutics, Return On Capital Employed regression line of its data series had standard deviation of  0.21 and standard deviation of  0.21. View All Fundamentals
 
Return On Capital Employed  
First Reported
2010-12-31
Previous Quarter
(0.37)
Current Value
(0.35)
Quarterly Volatility
0.2134262
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Anika Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anika Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.9 M, Interest Expense of 1.3 M or Selling General Administrative of 103.5 M, as well as many indicators such as Price To Sales Ratio of 3.33, Dividend Yield of 0.0 or PTB Ratio of 1.73. Anika financial statements analysis is a perfect complement when working with Anika Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

Latest Anika Therapeutics' Return On Capital Employed Growth Pattern

Below is the plot of the Return On Capital Employed of Anika Therapeutics over the last few years. It is Anika Therapeutics' Return On Capital Employed historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anika Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Return On Capital Employed10 Years Trend
Slightly volatile
   Return On Capital Employed   
       Timeline  

Anika Return On Capital Employed Regression Statistics

Arithmetic Mean0.03
Geometric Mean0.15
Coefficient Of Variation624.02
Mean Deviation0.18
Median0.11
Standard Deviation0.21
Sample Variance0.05
Range0.6926
R-Value(0.56)
Mean Square Error0.03
R-Squared0.31
Significance0.03
Slope(0.03)
Total Sum of Squares0.64

Anika Return On Capital Employed History

2024 -0.35
2023 -0.37
2022 -0.0604
2021 -0.0582
2020 -0.044
2019 0.11
2018 0.0812

About Anika Therapeutics Financial Statements

Anika Therapeutics investors utilize fundamental indicators, such as Return On Capital Employed, to predict how Anika Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Return On Capital Employed(0.37)(0.35)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.51)
Earnings Share
(6.64)
Revenue Per Share
11.139
Quarterly Revenue Growth
(0.07)
Return On Assets
(0.04)
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.